Parkinson's disease is the second commonest neurodegenerative disorder, after Alzheimer's, and represents a major cause of neurological morbidity globally. The diagnosis is made clinically and management is currently restricted to symptomatic treatments, with levodopa continuing to form the cornerstone of pharmacological therapy. Deep brain stimulation of specific basal ganglia targets can offer significant symptomatic benefits in selected patient groups. To date, no established disease-modifying agents that can halt or reverse the underlying neurodegenerative process are available in clinical practice. The aim of this article is to provide an overview, and an update, on the diagnosis and management of Parkinson's disease. Idiopathic Parkinson’s disease (PD) is the second commonest neurodegenerative disease, after Alzheimer’s, with an estimated lifetime risk of nearly 3-7%. From 1990 to 2016, the worldwide burden of PD has increased from an estimated 2.5 to 6.1 million patients. With age representing the biggest risk factor for the disease, and in the context of an exponentially ageing population, the prevalence of PD is predicted to continue to rise. Parkinson's disease Conferences will provide a global platform to discuss the latest advancements in research and therapies of it and will be discussed at Neuro Forum 2023.